Nanotechnology Now - Press Release: Arrowhead to Report Fiscal 2013 Fourth Quarter and Year-End Financial Results - Conference Call Scheduled for Wednesday, December 18, 2013

Home > Press > Arrowhead to Report Fiscal 2013 Fourth Quarter and Year-End Financial Results - Conference Call Scheduled for Wednesday, December 18, 2013

Abstract:
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will report its financial results for the fiscal 2013 fourth quarter and year ended September 30, 2013, on Wednesday, December 18, 2013, at 4:30 p.m. Eastern time. To participate in the conference call, please dial 877-300-8521 (toll free from the US), 855-669-9657 (toll free from Canada), or 412-317-6026 (for international callers). Investors may also access a live audio webcast of this conference call on the Company's website at www.arrowheadresearch.com.

Arrowhead to Report Fiscal 2013 Fourth Quarter and Year-End Financial Results - Conference Call Scheduled for Wednesday, December 18, 2013

Pasadena, CA | Posted on December 12th, 2013

A replay of the webcast will be available approximately one hour after the conclusion of the call and will remain available for 90 days. An audio replay will also be available approximately two hours after the conclusion of the call and will be available for 30 days. The audio replay can be accessed by dialing 877-870-5176 (toll free from the US and Canada), or 858-384-5517 (for international callers) and entering Event ID 10038065.

####

About Arrowhead Research Corporation
Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary drug delivery technologies to develop targeted drugs based on the RNA interference mechanism that efficiently silence disease-causing genes. Arrowhead technologies also enable partners to create peptide-drug conjugates that specifically home to cell types of interest while sparing off-target tissues. Arrowhead's pipeline includes clinical programs in chronic hepatitis B virus and obesity and partner-based programs in oncology.

For more information please visit www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list to receive news directly, please send an email to

For more information, please click here

Contacts:
Arrowhead Research Corporation
Vince Anzalone, CFA
626-304-3400

The Trout Group
Lauren Glaser
646-378-2972

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: